HIV-associated lipodystrophy

📋Clinical Description

This code represents the abnormal distribution of body fat, specifically lipodystrophy, that occurs in individuals with Human Immunodeficiency Virus (HIV) infection. It can manifest as fat loss (lipoatrophy) in the face, limbs, or buttocks, and/or fat accumulation (lipohypertrophy) in areas like the abdomen, dorsocervical region ("buffalo hump"), or breasts. This condition is often a side effect of antiretroviral therapy (ART) but can also be associated with HIV infection itself.

🎯When to Use

Use this code when documentation explicitly states "HIV-associated lipodystrophy" or describes the characteristic fat redistribution patterns in an HIV-positive patient. This diagnosis is typically supported by physician notes detailing the physical examination findings of lipoatrophy and/or lipohypertrophy in the context of a confirmed HIV diagnosis.

💡Coding Tips

Always sequence the code for HIV disease (B20) as the primary diagnosis when present.
Distinguish from other forms of lipodystrophy not associated with HIV; this code is specific to the HIV context.
Ensure documentation clearly links the lipodystrophy to the patient's HIV status or ART regimen.

AI-generated reference — verify against official guidelines

Clinical Notes

Code first

any human immunodeficiency virus [HIV] disease (B20)

Use additional code

code for adverse effect, if applicable, to identify drug (T37.5X5-)

Code Hierarchy

▲E88.1Lipodystrophy, not elsewhere classified

E88.14(current)

Same Category

E88Other and unspecified metabolic disorders E88.0Disorders of plasma-protein metabolism, NEC E88.01Alpha-1-antitrypsin deficiency E88.02Plasminogen deficiency E88.09Oth disorders of plasma-protein metabolism, NEC E88.1Lipodystrophy, not elsewhere classified E88.10